ArticleFrontiers in pharmacology2026
Shikonin inhibits MRSA biofilm formation to alleviate periprosthetic joint infection.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sequential eradication of bacterial persisters: integrating phytochemical pharmacology with microenvironment-responsive delivery strategies.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To alleviate periprosthetic joint infection (PJI) with methicillin-resistant Methods: The rat model of periprosthetic joint infection was established, utilizing techniques such as scanning electron microscopy and pathology test to evaluate the MRSA inhibitory of bacterial load and biofilm formation effects of SKN. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) experiments were conducted to assess the antibacterial activity of SKN. The crystal violet staining method was employed to evaluate the effects of SKN on MRSA biofilm formation and eradication. Transcriptomic and amino acid metabolomics analyses were used to investigate the mechanism of SKN inhibition in MRSA biofilm formation. Total thiol detection was used to assess the impact of SKN on the intracellular cysteine levels in MRSA. Finally, MIC and crystal violet staining were used to evaluate the antibacterial effects and biofilm eradication efficacy of SKN against clinical MRSA strains. Results: Conclusion: SKN inhibits MRSA by suppressing biofilm formation, effectively alleviating periprosthetic joint infection by MRSA, and the mechanism of SKN antibacterial activity may be related to regulate the cysteine metabolism in MRSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.